According to Clarivate epidemiology, more than 30 million people in the United States experience migraines. Migraine prophylaxis, despite being underused, is a core treatment approach to reduce the frequency, severity, and duration of migraines. Prescription options include a diverse mix of on- and off-label oral drugs—AbbVie / Allergan’s Botox, four anti-CGRP MAbs, and most recently, two oral CGRP antagonists. Prophylaxis is both individualized and dynamic, as physicians adjust regimens to improve outcomes and/or avoid side effects. Understanding this patient journey provides needed context for new and existing players as the prophylactic market becomes increasingly competitive.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Amgen / Novartis, Eli Lilly, Teva, Lundbeck, AbbVie / Allergan, Supernus Pharmaceuticals, Upsher-Smith, and Janssen-Cilag.
Key drugs: Aimovig, Emgality, Ajovy, Vyepti, Botox, Trokendi XR, Qudexy XR, topiramate IR/XR, propranolol, amitriptyline, verapamil.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.